Zentek's Progress on Influenza Countermeasure Using Multivalent Aptamer Technology

Zentek Ltd. has announced the completion of initial in vivo testing for its lead candidate countermeasure targeting H1N1 seasonal influenza. This development is part of the Innovative Solutions Canada Testing Stream, with Zentek receiving approximately $1.1 million from the Canadian government for the project.

The testing involved a mouse model under the supervision of Dr. Matthew Miller at McMaster University. Results indicated improved clinical outcomes, with animals receiving the aptamer lead candidate showing significantly better survival rates and faster recovery than the control group.

The aptamer countermeasure, developed with multivalent technology, targets various influenza strains. The promising results have prompted further research to refine the formulation and evaluate the treatment's efficacy against both H1N1 and H5N1 strains in upcoming tests.